Evon, Donna M.
Golin, Carol E.
Ruffin, Rachel
Ayres, Shauna
Fried, Michael W.
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (K23DK089004-04, K24DK066144, DK034987)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (K24HD06920)
National Institute of Allergy and Infectious Diseases (P30AI450410)
Article History
Received: 2 April 2017
Accepted: 2 May 2018
First Online: 27 June 2018
Ethics approval and consent to participate
: This study was approved by the University of North Carolina at Chapel Hill’s Institutional Review Board (IRB# 12-2323). All study participants provided written consent to participate in the study prior to data collection.
: Donna Evon has served as an ad hoc consultant and receives grant support from Gilead. Michael Fried has received research funding from and served as a consultant for AbbVie, BMS, Gilead, and Merck. He serves as consultant to TARGET PharmaSolutions. The remaining authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.